Aurobindo Pharma’s Expansion Analyzed

Aurobindo Pharma’s stock price went up by 1.42% after a key move: their subsidiary, Auro Pharma, bought a significant part of Khandelwal Laboratories’ business. This included medicines for everyday illnesses, not cancer, and a plan for new medicines. This deal is good news for Aurobindo Pharma because it helps them grow in the Indian medicine market.

Key Points

• Auro Pharma acquired Khandelwal Labs’ non-oncology business.
• The deal involved Rs 325 crore in cash payment.
• New medicines for pain and infections will be added to Aurobindo.
• Khandelwal Labs had a strong portfolio with Rs 113.53 crore turnover.
• This expansion strengthens Aurobindo’s position in the domestic market.
• The transaction completed on January 1, 2026, as agreed.

About Khandelwal Laboratories

Khandelwal Laboratories is a company that makes and sells medicines in India. They focus on creating their own brands of medicine – these are called “branded formulations.” They make medicines for both cancer and for treating regular illnesses. They have a lot of different kinds of medicine available, like those for fighting infections and for managing pain.

About the Deal

Auro Pharma bought Khandelwal Laboratories’ non-oncology business for Rs 325 crore. This means they got all the medicines, the ideas for new medicines, the people working there, and all the agreements. It’s like buying a whole business, making it a part of Aurobindo Pharma.

What This Means for Aurobindo Pharma

Aurobindo Pharma already makes many medicines, including active ingredients (the stuff that makes a medicine work). This new business will help them grow their range of painkillers and medicines to fight infections. This is important because the market for these types of medicines is growing in India.

Aurobindo Pharma’s Recent Performance

Aurobindo Pharma’s profits and sales have been increasing. In the last quarter (Q2 FY26), their profits went up by 3.8% and their sales went up by 7.7%. This shows that the company is doing well and expanding.

Expanding into new markets and product lines is key to long-term pharmaceutical success.